Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)

摘要

Background: Generic-name drugs are chemically equivalent to their brand-name counterparts. However, the clinical efficacy and safety may not be equivalent between the brand-name (Lipanthyl) and generic-name (fenolip) fenofibrate in treating hypertriglyceridemia. The objective of this study was toinvestigate the efficacy and safety of brand- and generic-name fenofibrate in patients with hypertriglyceridemia. Methods: A total of 114 consecutive patients from January 2008 to December 2009 diagnosed with hypertriglyceridemia were enrolled in this study, including 57 patients receiving Lipanthyl (200mg/day) and another 57 patients treated with fenolip (200mg/day). Serum cholesterol, triglyceride (TG), high-density lipoprotein (HDL) cholesterol, glucose, creatinine, uric acid, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels were evaluated before and 3-6 months after the treatment. Results: With regard to clinical efficacy, both drugs were found to significantly decrease the serum levels of TG (297±125 to 165±73mg/dL, p
原文英語
頁(從 - 到)136-138
頁數3
期刊Journal of Experimental and Clinical Medicine(Taiwan)
5
發行號4
DOIs
出版狀態已發佈 - 八月 2013

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Comparisons of clinical efficacy and safety between the brand- and generic-name fenofibrate in patients with hypertriglyceridemia」主題。共同形成了獨特的指紋。

引用此